StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) bonds

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$591.00M
Long-term debt
Net debt
-$1.13B
After $1.72B of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in Moderna's 10-Q for the period ended Jun 30, 2026

Moderna's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
(DDTL)-1$400.00M–
(DDTL)-2$500.00M–
Delayed Draw Term Loan$900.00M–
Initial Term Loan$600.00M$591.00M
Secured Debt$1.50B–

See a number that looks wrong?